Research programme: eye disorder gene therapies - Astellas Pharma/4D Molecular Therapeutics
Latest Information Update: 08 Sep 2023
At a glance
- Originator 4D Molecular Therapeutics
- Developer 4D Molecular Therapeutics; Astellas Pharma
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Eye disorders
Most Recent Events
- 10 Jul 2023 Astellas Pharma in-licenses AAV vector discovery and optimisation technology from 4D Molecular Therapeutics
- 10 Jul 2023 Early research in Eye disorders in Japan (Intravitreous), prior to July 2023
- 10 Jul 2023 Early research in Eye disorders in USA (Intravitreous), prior to July 2023